Contraindications
- None listed in the retrieved insert
Dosing: Adult
- Gastrointestinal symptoms of chronic gastritis: 15 mg/day in 3 divided doses; reassess at about 2 weeks; older adults may need 7.5 mg/day
- Adjunct to bowel preparation before barium enema: 20 mg at the start of the lavage solution and 20 mg after it is finished
Dosing: Altered kidney function
Mosapride is a serotonin 5-HT4 agonist prokinetic metabolized by CYP3A4; only 0.1% of a dose is excreted unchanged in urine. The Japanese insert does not address kidney impairment but advises caution and dose reduction (for example 7.5 mg/day) in older adults, and warns of fulminant hepatitis. It has no US FDA label.
Kidney function measure: The Japanese insert does not address kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Chronic gastritis symptoms: 15 mg/day in 3 divided doses before or after meals; reassess after about 2 weeks (PMDA insert).
- CrCl 30–59 mL/min
- Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
- CrCl 15–29 mL/min
- Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
- CrCl <15 mL/min (not on dialysis)
- Mostly hepatic (0.1% unchanged in urine); the Japanese insert gives no kidney dosing and there are no CKD data. Consider 7.5 mg/day if adverse effects occur, as for older adults (insert 9.8).
- Hemodialysis (intermittent)
- Not studied in dialysis; no dose given.
- Peritoneal dialysis
- Not studied in dialysis; no dose given.
- CRRT
- Not studied in dialysis; no dose given.
- Dialyzable? Not stated (99% protein-bound).
- Monitoring Liver function: fulminant hepatitis and severe liver dysfunction reported (some fatal); avoid prolonged use without reassessment; stop for fatigue, anorexia, dark urine or jaundice (PMDA insert).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: PMDA (Japan) product information (October 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- No pediatric trials (PMDA insert).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 5 mg
- Controlled-release tablet: 15 mg
Registered products in the Philippines
4 products registered with the Food and Drug Administration (FDA) Philippines list Mosapride as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products4
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
GasmotinMosapride citrate (as dihydrate) | 5 mg Film-Coated TabletAlu/PVC Blister Pack x 10's with aluminum wrapping (Box of 30's) | Rx | Interthai Pharmaceutical Manufacturing Ltd.Thailand | Zuellig Pharma CorporationImporter: Hi-Eisai Pharmaceutical Inc. | DR-XY35905 | Jul 30, 2030 | |
Gastiin CRMosapride citrate (as dihydrate) | 15 mg Controlled Release TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Korea United Pharm. Inc.Korea | United Douglas Pharm. Philippines, Inc. | DR-XY 48036 | May 25, 2027 | |
GastoridMosapride Citrate | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Aju Pharm Co., Ltd.Republic of Korea | Kaufmann Pharma Inc.Importer: Ambica International Corporation | DRP-6554-01 | Apr 27, 2037 | |
GutmovinMosapride Citrate | 5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Aju Pharm Co., Ltd.Republic of Korea | Justright Healthcare Inc.Importer: Ambica International Corporation | DRP-6554 | Mar 4, 2038 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Anticholinergics (atropine, butylscopolamine) | Minor | Reduced prokinetic effect. | Separate doses. |
| Erythromycin and other CYP3A4 inhibitors | Minor | Erythromycin raised mosapride Cmax about 1.6-fold (42.1 to 65.7 ng/mL) and half-life from 1.6 to 2.4 hours (insert 16.7.1). | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Serious
- Fulminant hepatitis, severe liver dysfunction, jaundice (some fatal)
Monitoring parameters
- Liver function: fulminant hepatitis and severe liver dysfunction reported (some fatal); avoid prolonged use without reassessment; stop for fatigue, anorexia, dark urine or jaundice (PMDA insert). Kidney
- Liver function and symptoms of hepatitis
Pharmacokinetics
Key PK parameters
| Time to peak | 0.8 hour |
|---|---|
| Half-life | 2.0 hours |
| Protein binding | 99.0% |
| Metabolism (CYP, transporters) | Hepatic, mainly CYP3A4 |
| Renal excretion kidney | 0.1% unchanged and 7.0% as main metabolite in urine (48 hours) |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Pharmaceuticals and Medical Devices Agency (Japan). Mosapride citrate tablets "NP" package insert [PMDA (Japan) product information, October 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190665102
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Nipro Corporation. (2023). Mosapride citrate tablets 2.5 mg and 5 mg "NP" [Japanese package insert, 1st edition, revised October 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987190665102
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .